Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality

Cancer Research

Volumn 72, Issue 19, 2012, Pages 4954-4962

  Nagoshi, Hisao ^a   Taki, Tomohiko ^a   Hanamura, Ichiro ^b   Nitta, Masakazu ^b   Otsuki, Takemi ^c   Nishida, Kazuhiro ^a   Okuda, Keiko ^a   Sakamoto, Natsumi ^a   Kobayashi, Satoru ^a   Yamamoto Sugitani, Mio ^a   Tsutsumi, Yasuhiko ^a   Kobayashi, Tsutomu ^a   Matsumoto, Yosuke ^a   Horiike, Shigeo ^a   Kuroda, Junya ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CENTROMERE; CHIMERA; CHROMOSOME 8Q; CHROMOSOME BREAKAGE; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; COPY NUMBER VARIATION; DNA MICROARRAY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NBEA GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PVT1 GENE; SPECTRAL KARYOTYPING; WWOX GENE;

CARRIER PROTEINS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 4; CHROMOSOMES, HUMAN, PAIR 8; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDOREDUCTASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPECTRAL KARYOTYPING; TUMOR SUPPRESSOR PROTEINS;

EID: 84867134177     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0213     Document Type: Article

References (50)

1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
2. Chen KC, Bevan PC, Matthews JG. Analysis of G banded karyotypes in myeloma cells. J Clin Pathol 1986;39:260-6. (Pubitemid 16116176)
3. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724-32. (Pubitemid 44316143)
4. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988;71:453-6. (Pubitemid 18089536)
5. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-9.
6. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526-34. (Pubitemid 27299091)
7. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R, et al. Intergroupe Francophone du Myélome. Rearrangementsof the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001;98:3082-6.
8. Sawyer JR, Lukacs JL, Thomas EL, Swanson CM, Goosen LS, Sammartino G, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001;112:167-74. (Pubitemid 32151165)
9. Fabris S, Storlazzi CT, Baldini L, Nobili L, Lombardi L, Maiolo AT, et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Genes Chromosomes Cancer 2003;37:261-9. (Pubitemid 36667564)
10. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with cmyc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97:228-33. (Pubitemid 30055813)
11. Dib A, Gabrea A, Glebov OK, Bergsagel PL, Kuehl WM. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008;39:25-31.
12. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, TerréC, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and theGroupe Français de Cytogénétique Hématologique. Blood 2001;97:822-5. (Pubitemid 32113422)
13. Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. Am J Hematol 2007;82:1080-7. (Pubitemid 350209850)
14. Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood 1990;75:1848-52. (Pubitemid 20161500)
15. Shtivelman E, Bishop JM. Effects of translocations on transcription from PVT. Mol Cell Biol 1990;10:1835-9.
16. Hanamura I, Goto M, Nagoshi H, Taki T, Imai N, Suganuma K, et al. Establishment and characterization of a novel human myeloma cell line, AMU-MM1, from a multiple myeloma patient involving central nerve system after treatment with bortezomib. Blood 2010;116: (abstract [4991]).
17. Taniwaki M, Sliverman GA, Nishida K, Horiike S, Misawa S, Shimazaki C, et al. Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood 1995;86:1481-6.
18. Kakazu N, Taniwaki M, Horiike S, Nishida K, Tatekawa T, Nagai M, et al. Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer 1999;26:336-45. (Pubitemid 29529579)
19. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN: an international system of human cytogenetic nomenclature. Basel, Switzerland: Karger; 2009.
20. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005;65:6071-9. (Pubitemid 40994391)
21. Chinen Y, Taki T, Nishida K, Shimizu D, Okuda T, Yoshida N, et al. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t (2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene 2008;27: 2249-56. (Pubitemid 351483379)
22. Henglein B, Synovzik H, Groitl P, Bornkamm GW, Hartl P, Lipp M. Three breakpoints of variant t(2;8) translocations in Burkitt's lymphoma cells fall within a region 140 kilobases distal from c-myc. Mol Cell Biol 1989;9:2105-13. (Pubitemid 19117811)
23. Rack KA, Delabesse E, Radford-Weiss I, Bourquelot P, Le Guyader G, Vekemans M, et al. Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. Genes Chromosomes Cancer 1998;23:220-6. (Pubitemid 28465638)
24. Villeneuve L, Rassart E, Jolicoeur P, Graham M, Adams JM. Proviral integration site Mis-1 in rat thymomas corresponds to the pvt-1 translocation breakpoint in murine plasmacytomas. Mol Cell Biol 1986;6:1834-7. (Pubitemid 16121276)
25. Huppi K, Siwarski D. Chimeric transcripts with an open reading frame are generated as a result of translocation to the Pvt-1 region in mouse B-cell tumors. Int J Cancer 1994;59:848-51.
26. Asker C, Mareni C, Coviello D, Ingvarsson S, Sessarego M, Origone P, et al. Amplification of c-myc and pvt-1 homologous sequences in acute nonlymphatic leukemia. Leuk Res 1988;12:523-7.
27. Shtivelman E, Bishop JM. The PVT gene frequently amplifies with MYC in tumor cells. Mol Cell Biol 1989;9:1148-54. (Pubitemid 19071683)
28. Bakkus MH, Brakel-van Peer KM, Michiels JJ, van't Veer MB, Benner R. Amplification of the c-myc and the pvt-like region in human multiple myeloma. Oncogene 1990;5:1359-64.
29. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006;103:7024-9.
30. Carramusa L, Contino F, Ferro A, Minafra L, Perconti G, Giallongo A, et al. The PVT-1 oncogene is a Mycprotein target that is overexpressed in transformed cells. J Cell Physiol 2007;213:511-8. (Pubitemid 47509734)
31. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 2007;13:5745-55. (Pubitemid 47583899)
32. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE, et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008;6:212-21. (Pubitemid 351342409)
33. Palumbo AP, Boccadoro M, Battaglio S, Corradini P, Tsichlis PN, Huebner K, et al. Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3′ of the myc gene, is rearranged in multiple myelomas. Cancer Res 1990;50:6478-82. (Pubitemid 20348763)
34. Wang X, Herberg FW, Laue MM, Wullner C, Hu B, Petrasch-Parwez E, et al. Neurobeachin: a protein kinase A-anchoring, beige/Chediakhigashi protein homolog implicated in neuronal membrane traffic. J Neurosci 2000;20:8551-65.
35. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692-700. (Pubitemid 46239604)
36. O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Kilimann MW, et al. Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Exp Hematol 2009;37:234-44.
37. Sáez B, Martín-Subero JI, Largo C, Martín MC, Odero MD, Prosper F,et al. Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses. Cancer Genet Cytogenet 2006;169:143-9. (Pubitemid 44382606)
38. Chiecchio L, Dagrada GP, Protheroe RK, Stockley DM, Smith AG, Orchard KH, et al. UK Myeloma Forum. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009;94:1024-8.
39. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A 2004;101:4401-6. (Pubitemid 38437424)
40. Watanabe A, Hippo Y, Taniguchi H, Iwanari H, Yashiro M, Hirakawa K, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003;63:8629-33. (Pubitemid 38064037)
41. Savelyeva L, Sagulenko E, Schmitt JG, Schwab M. The neurobeachin gene spans the common fragile site FRA13A. Hum Genet 2006;118:551-8. (Pubitemid 41825127)
42. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5. (Pubitemid 30225175)
43. Fu DY, Wang ZM, Wang BL, Chen L, Yang WT, Shen ZZ, et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol 2010;41:48-58.
44. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30. (Pubitemid 47199123)
45. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44. (Pubitemid 47208626)
46. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factorkappaB signaling pathways in Waldenstroms macroglobulinemia. Cancer Res 2009;69:3579-88.
47. Giefing M, Arnemann J, Martin-Subero JI, Nieländer I, Bug S, Hartmann S, et al. Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. Br J Haematol 2008;142:916-24.
48. Ohta M, Mimori K, Fukuyoshi Y, Kita Y, Motoyama K, Yamashita K, et al. Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer 2008;98:410-7. (Pubitemid 351161238)
49. Shibata K, Mori M, Tanaka S, Kitano S, Akiyoshi T. Identification and cloning of human G-protein gamma 7, down-regulated in pancreatic cancer. Biochem Biophys Res Commun 1998;246:205-9. (Pubitemid 28413952)
50. Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, et al. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol 2011;39:817-28.